General Pharmacology Practice Questions

Q: Which of the following statements regarding enzyme inhibition is true?

Fluoroacetate competitively inhibits aconitase.. ### Explanation **Correct Option: D. Fluoroacetate competitively inhibits aconitase.** Fluoroacetate is a classic example of **"Lethal Synthesis."** It is not toxic itself but is converted in the body to **fluorocitrate**. Fluorocitrate then acts as a competitive inhibitor of the enzyme **aconitase** in the Krebs cycle. This blockade halts cellular respiration, leading to toxicity. **Analysis of Incorrect Options:** * **A. Sulfonamides:** These are structural analogs of PABA and **competitively** (not irreversibly) inhibit **Dihydropteroate synthase**. It is *Trimethoprim* and *Methotrexate* that inhibit Dihydrofolate reductase. * **B. Ethanol in Methanol Poisoning:** Ethanol acts as a **competitive inhibitor** of Alcohol Dehydrogenase (ADH). By having a higher affinity for ADH, ethanol prevents the conversion of methanol into its toxic metabolites (formaldehyde and formic acid). * **C. Malathion:** This is an organophosphate that inhibits Acetylcholinesterase **irreversibly** (covalent bonding). Unlike competitive inhibition, irreversible inhibition **cannot** be reversed by simply increasing the substrate (Acetylcholine) concentration. **NEET-PG High-Yield Pearls:** 1. **Competitive Inhibition:** $V_{max}$ remains unchanged, $K_m$ increases. It can be overcome by increasing substrate concentration (e.g., Neostigmine for Curare poisoning). 2. **Non-competitive Inhibition:** $V_{max}$ decreases, $K_m$ remains unchanged (e.g., Acetazolamide, Digoxin). 3. **Suicide Inhibition:** A form of irreversible inhibition where the enzyme converts an inactive substrate into a reactive inhibitor that binds permanently (e.g., Allopurinol to Alloxanthine, Aspirin, 5-Fluorouracil).

Q: Pharmacoepidemiology is associated with which phase of clinical trials?

Phase V. **Explanation:** **1. Why Phase V is the Correct Answer:** While Phase IV (Post-Marketing Surveillance) involves monitoring the safety and efficacy of a drug in the general population, **Phase V** specifically refers to **Pharmacoepidemiology** and translational research. It focuses on the study of drug effects, risks, and benefits in large populations over long periods using epidemiological methods [1]. It evaluates how a drug performs in "real-world" clinical practice compared to the controlled environment of clinical trials, often influencing public health policies and guidelines. **2. Why Other Options are Incorrect:** * **Phase 0 (Microdosing):** These are human microdosing studies conducted in a small number of subjects (10–15) to study pharmacokinetics (PK) and pharmacodynamics (PD) before Phase I. * **Phase II (Therapeutic Exploratory):** This phase tests the drug on a small group of patients (100–300) to determine efficacy and establish the therapeutic dose range [1]. * **Phase IV (Post-Marketing Surveillance):** This phase begins after the drug is marketed to detect rare adverse effects. While closely related, Pharmacoepidemiology is technically categorized as Phase V in modern clinical research frameworks. **3. High-Yield Clinical Pearls for NEET-PG:** * **Phase I:** Safety and Tolerability (usually in healthy volunteers, except for anti-cancer drugs) [2]. * **Phase III:** Therapeutic Confirmatory (large-scale RCTs; the basis for New Drug Application/NDA). * **Phase IV:** Detects "Rare Adverse Events" (e.g., Phocomelia, which led to the strengthening of these trials). * **Phase V:** Focuses on the "Effectiveness" in the community and long-term population impact. * **N-of-1 Trials:** A trial where a single patient is the sole subject, often used to determine the best treatment for that specific individual.

Q: Basiliximab is a monoclonal antibody against which receptor?

IL-2 receptor. **Explanation:** **Basiliximab** is a chimeric monoclonal antibody (mouse-human) that acts as a potent immunosuppressant. Its mechanism of action involves binding specifically to the **α-subunit (CD25)** of the **Interleukin-2 (IL-2) receptor** expressed on the surface of activated T-lymphocytes. By competitively inhibiting IL-2 from binding to its receptor, it prevents T-cell proliferation and activation, which are critical steps in the immune response against transplanted organs. **Analysis of Options:** * **Option A (IL-2 receptor):** Correct. Basiliximab (and Daclizumab) are IL-2 receptor antagonists used primarily as "induction therapy" in renal transplantation to prevent acute organ rejection. * **Option B (CD20):** Incorrect. **Rituximab** is the monoclonal antibody directed against CD20, primarily used in B-cell non-Hodgkin lymphomas and Rheumatoid Arthritis. * **Option C (INF-α):** Incorrect. While there are no major monoclonal antibodies targeting INF-α used in standard transplant protocols, drugs like Sifalimumab have been studied for SLE. * **Option D (IL-6):** Incorrect. **Tocilizumab** and Sarilumab are the monoclonal antibodies that target IL-6 receptors, used in Rheumatoid Arthritis and Cytokine Release Syndrome (CRS). **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Prophylaxis of acute organ rejection in renal transplants (Induction therapy). * **Mnemonic:** "Basiliximab binds the **B**-chain (actually the alpha chain/CD25) to block the **B**-last (T-cell blast/proliferation)." * **Side Effects:** Generally well-tolerated; unlike older agents, it does not typically cause cytokine release syndrome. * **Comparison:** Unlike Muromonab-CD3 (which depletes T-cells), Basiliximab only inhibits *activated* T-cells.

Q: Which of the following statements about phase IV clinical trials is true?

It is post-marketing surveillance of drugs. **Explanation:** **Phase IV Clinical Trials** are also known as **Post-Marketing Surveillance (PMS)**. These trials begin after a drug has been approved by regulatory authorities (like the FDA or CDSCO) and is available on the market for the general population. 1. **Why Option C is Correct:** Unlike Phase I-III trials, which involve a limited number of selected participants under controlled conditions, Phase IV monitors the drug's performance in the "real world." Its primary goal is to detect **rare adverse effects**, long-term risks, and benefits that were not evident during the shorter, smaller pre-approval trials. 2. **Why Other Options are Incorrect:** * **Option A:** Drugs for pediatric use undergo specific pediatric clinical trials (often Phase IIIb), but Phase IV is not defined by the age group; it is defined by the timing (post-approval). * **Option B:** Drugs for rare diseases are called **Orphan Drugs**. While they undergo Phase IV like any other drug, Phase IV itself is not a study specifically "for rare drugs." * **Option C:** "Human pharmacology and safety studies" refers to **Phase I** clinical trials, where the drug is first tested in a small group of healthy volunteers to determine safety and pharmacokinetics. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Microdosing studies (sub-therapeutic doses) used to determine PK parameters. * **Phase I:** Safety and Tolerability (Healthy volunteers, except for oncology drugs). * **Phase II:** Therapeutic **Exploration** (Small group of patients; determines dose-range). * **Phase III:** Therapeutic **Confirmation** (Large multicentric RCTs; establishes efficacy against placebo or gold standard). * **Phase IV:** Post-marketing surveillance; identifies **idiosyncratic reactions** and rare side effects (e.g., the withdrawal of Rofecoxib due to cardiovascular risks).

Q: The rate of elimination with first-order kinetics is proportional to which of the following?

Plasma concentration. ### Explanation In **First-Order Kinetics** (Linear Kinetics), a constant **fraction** of the drug is eliminated per unit of time. This means the actual amount of drug removed is directly proportional to the amount of drug present in the body. **1. Why Option A is Correct:** The mathematical equation for the rate of elimination is: **Rate of elimination = CL × C** *(Where CL = Clearance and C = Plasma Concentration)* Since clearance remains constant in first-order kinetics, the rate of elimination increases linearly as the plasma concentration increases. Most drugs follow this pattern at therapeutic doses. **2. Why Other Options are Incorrect:** * **B. Loading Dose:** This is the initial dose given to achieve target plasma concentration rapidly. It determines the starting concentration but does not dictate the ongoing *rate* of elimination. * **C. Maintenance Dose:** This is the dose required to maintain a steady state. While it is calculated based on the clearance, the rate of elimination itself is driven by the concentration achieved, not the dose administered. * **D. Renal Plasma Flow:** While renal flow affects the clearance of drugs primarily excreted by the kidneys, it is a physiological parameter of the organ, not the kinetic principle defining the rate of elimination for all drugs. ### High-Yield Clinical Pearls for NEET-PG: * **First-Order Kinetics:** Constant **fraction** eliminated; Half-life ($t_{1/2}$) is **constant**; most drugs follow this. * **Zero-Order Kinetics:** Constant **amount** eliminated; Half-life is **variable** (proportional to concentration). * **Mnemonic for Zero-Order Drugs:** **"WATT"** – **W**arfarin (at high doses), **A**lcohol/Aspirin, **T**heophylline, **T**olbutamide/Pheny**t**oin. * **Steady State:** Reached after **4–5 half-lives**, regardless of the dose or frequency of administration.

Q: Which of the following properties of a drug will enable it to be used in low concentration?

High affinity. **Explanation:** The correct answer is **High affinity**. **1. Why High Affinity is Correct:** Affinity refers to the chemical force that causes a drug to bind to its receptor. It is the measure of how tightly a drug binds to its target. In pharmacological terms, affinity is inversely proportional to the **Dissociation Constant ($K_d$)**. A drug with high affinity requires a very low concentration to occupy 50% of the available receptors. Therefore, drugs with high affinity can achieve their desired pharmacological effect even at low doses or concentrations. **2. Why Other Options are Incorrect:** * **High Specificity:** Specificity refers to the ability of a drug to act on a particular receptor type or tissue. While highly specific drugs have fewer side effects, specificity does not dictate the *amount* or *concentration* of the drug needed to trigger a response. * **Low Specificity:** This implies the drug binds to multiple receptor types (promiscuity), which usually leads to a higher incidence of adverse effects, but it does not determine the potency or concentration required for action. * **High Stability:** This relates to the drug's resistance to degradation (metabolism) and its shelf-life. While stability affects the duration of action and storage, it does not determine the concentration needed to initiate a receptor-mediated response. **3. NEET-PG High-Yield Pearls:** * **Potency vs. Efficacy:** Affinity is a major determinant of **Potency** (the amount of drug needed for an effect). **Efficacy** (Intrinsic Activity) is the ability of the drug to activate the receptor once bound. * **$K_d$ Relationship:** A lower $K_d$ value signifies higher affinity. * **Agonists vs. Antagonists:** Both agonists and antagonists possess affinity, but only agonists possess intrinsic activity (efficacy).

Q: Which of the following is not an alkaloid?

Neostigmine. **Explanation:** The core concept behind this question lies in distinguishing between **natural alkaloids** and **synthetic/semi-synthetic compounds**. **Why Neostigmine is the correct answer:** Alkaloids are naturally occurring organic nitrogenous compounds, mostly derived from plants, that produce physiological actions. **Neostigmine** is a **synthetic** quaternary ammonium compound. While it was structurally modeled after Physostigmine (a natural alkaloid from the Calabar bean), Neostigmine itself does not occur in nature. It is designed to be polar, meaning it does not cross the blood-brain barrier, unlike its natural counterpart. **Analysis of incorrect options:** * **Morphine:** A classic natural alkaloid derived from the opium poppy (*Papaver somniferum*). It is the prototype opioid analgesic. * **Emetine:** A natural alkaloid derived from the ipecacuanha root (*Cephaelis ipecacuanha*). It was historically used as an emetic and in the treatment of amoebiasis. * **Atropine:** A natural belladonna alkaloid extracted from plants like *Atropa belladonna* (Deadly Nightshade). It acts as a competitive antagonist at muscarinic receptors. **High-Yield NEET-PG Pearls:** * **Physostigmine vs. Neostigmine:** Physostigmine is a tertiary amine (natural alkaloid) that **crosses** the BBB (used for Atropine poisoning). Neostigmine is a quaternary ammonium (synthetic) that **does not cross** the BBB (used for Myasthenia Gravis and reversing neuromuscular blockade). * **Other common alkaloids:** Quinine, Reserpine, Vincristine, and Nicotine. * **Identification Test:** Alkaloids typically give a positive result with **Mayer’s reagent** (creamy precipitate) or **Dragendorff’s reagent** (orange-red precipitate).

Q: What is a specific side effect of thalidomide?

Phocomelia. **Explanation:** **Thalidomide** is a classic example of a potent **teratogen**. The correct answer is **Phocomelia**, a condition characterized by "seal-like limbs" where the long bones of the extremities are absent or significantly underdeveloped, causing the hands or feet to be attached directly to the trunk. 1. **Mechanism of Phocomelia:** Thalidomide was originally used in the 1950s as a sedative and anti-emetic for morning sickness. It was later discovered that exposure during the first trimester (specifically days 24–36 of gestation) inhibits angiogenesis and interferes with the protein **Cereblon**, which is essential for limb bud development. This led to the "Thalidomide Tragedy," resulting in thousands of babies born with phocomelia. 2. **Analysis of Incorrect Options:** * **Lymphopenia/Lymphocytosis:** Thalidomide has immunomodulatory effects (inhibits TNF-α), but it is not specifically known for causing significant fluctuations in lymphocyte counts as a primary diagnostic side effect. * **Optic Neuritis:** This is a classic side effect of **Ethambutol** (anti-tubercular drug), not thalidomide. Thalidomide is more commonly associated with peripheral neuropathy. **High-Yield Clinical Pearls for NEET-PG:** * **Current Uses:** Despite its teratogenicity, thalidomide is now a first-line treatment for **Multiple Myeloma** and **Erythema Nodosum Leprosum (ENL)**. * **Mechanism:** It acts by inhibiting **TNF-α** and angiogenesis. * **Regulatory Fact:** The thalidomide disaster led to the strengthening of the FDA and more stringent drug testing regulations (Kefauver-Harris Amendment). * **Contraception:** Due to its high teratogenic risk, it is strictly contraindicated in pregnancy (Category X) and requires the "STEPS" program for risk management.

Question 1

Which of the following statements regarding enzyme inhibition is true?

Accepted Answer

Fluoroacetate competitively inhibits aconitase.

Answer

Sulfonamides inhibit dihydrofolate reductase irreversibly.

Answer

Ethanol inhibits alcohol dehydrogenase when used in methanol poisoning.

Answer

Acetylcholinesterase inhibition by malathion can be reversed by increasing the levels of acetylcholine.

Question 2

Therapeutic Drug Monitoring (TDM) involves measurement of plasma concentrations of drugs to determine if the drug levels are within the therapeutic range. For TDM to be clinically useful, which of the following criteria should be fulfilled?

Accepted Answer

When the clinical response cannot be easily monitored.

Answer

There should be a good relationship between plasma concentration and drug dosage.

Answer

The relationship between plasma drug concentration and therapeutic response and/or toxicity should be poor.

Answer

When pharmacodynamic tolerance is suspected.

Question 3

Pharmacoepidemiology is associated with which phase of clinical trials?

Accepted Answer

Phase V

Answer

Phase 0

Answer

Phase II

Answer

Phase IV

Question 4

Basiliximab is a monoclonal antibody against which receptor?

Accepted Answer

IL-2 receptor

Answer

CD20

Answer

INF-α

Answer

IL-6

Question 5

Which of the following statements about phase IV clinical trials is true?

Accepted Answer

It is post-marketing surveillance of drugs

Answer

It is conducted for pediatric drugs

Answer

It is conducted for rare drugs

Answer

It is also called human pharmacology and safety studies

Question 6

The rate of elimination with first-order kinetics is proportional to which of the following?

Accepted Answer

Plasma concentration

Answer

Loading dose

Answer

Maintenance dose

Answer

Renal plasma flow

Question 7

Which of the following properties of a drug will enable it to be used in low concentration?

Accepted Answer

High affinity

Answer

High specificity

Answer

Low specificity

Answer

High stability

Question 8

Which of the following is not an alkaloid?

Accepted Answer

Neostigmine

Answer

Morphine

Answer

Emetine

Answer

Atropine

Question 9

A 500-mg dose of a drug has therapeutic efficacy for 6 hours. If the half-life of the drug is 8 hours, for how long would a 1-gm dose be effective?

Accepted Answer

14 hours

Answer

12 hours

Answer

16 hours

Answer

24 hours

Question 10

What is a specific side effect of thalidomide?

Accepted Answer

Phocomelia

Answer

Lymphopenia

Answer

Lymphocytosis

Answer

Optic neuritis

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?